Pregabalin in the treatment of XXXX : results of a multicenter chinese study.

@entity1 @entity697 @entity9 @entity158
OBJECTIVE: The aim of this study was to evaluate the efficacy, impact on quality of life, and safety of pregabalin for the treatment of @entity697 ( @entity697 ) and @entity9 ( @entity9 ). DESIGN: Multicenter, parallel-group, single-blind, 4-week, randomized clinical trial. SETTING: Conducted in the department of @entity158 clinic of participating hospitals. SUBJECTS: Three hundred @entity1 with @entity697 or @entity9 (of which 239 completed the study). METHODS: @entity1 were treated with oxycodone (A group) or combination of oxycodone and pregabalin (B group). @entity1 with @entity697 belonged to A1 group and B1 group. @entity1 with @entity9 belonged to A2 group and B2 group. @entity158 intensity was rated on an 11-point numerical rating scale (NRS). Other outcomes included mean daily oxycodone doses, quality of life, and adverse effects. RESULTS: Pregabalin-treated @entity1 had greater NRS decrement: 74% in B1 (vs 58% in A1; P   <   0.05); 69% in B2 (vs 53% in A2; P   <   0.05). Significant improvement in quality of life was observed in all groups, and pregabalin-treated @entity1 improved more, with 72.7% in B1 (vs 63.7% in A1; P   <   0.05) and 74.5% in B2 (vs 59.6% in A2; P   <   0.05). The maximum tolerated dose of oxycodone for pregabalin-treated @entity1 was lower. Pregabalin had acceptable tolerability. CONCLUSIONS: Both combination therapy with oxycodone plus pregabalin and oxycodone monotherapy were effective and safe for @entity9 . In addition, subjects on combination therapy showed shortened time to @entity158 relief, reduced @entity158 intensity, and greater improvement than oxycodone alone.
